# Application/Control No. O9/674,913 Reéxamination GAUDERNACK ET AL. Examiner Christopher Nichols, Ph.D. Applicant(s)/Patent Under Reéxamination GAUDERNACK ET AL. Page 1 of 5

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-5958684	09-1999	Van Leeuwen et al.	435/6
	В	US-5780587	07-1998	Potter	530/326
	С	US-5851996	12-1996	Kline	514/12
	D,	US-			
	Ε	US-			
	F	US-			·
	G	US-			
	н	US-			
	١	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 01/42306	06-2001	WIPO	·	C07K 14/705
	0	WO 97/12992	04-1997	WIPO		C12Q 1/68
	Р					
	Q					
	R					
	s	,				
	Т	/				

#### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Skolnick and Fetrow (2000) From Genes to Protein Strucuture and Function: Novel Applications of Computational Approaches in the Genomic Era. Trends in Biotech 18(1); 34-39.
	٧	Jobling et al. (1991) Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis. Mol. Microbiol. 5(7):1755-67.
	w	Monsonego et al. (2001) Immune Hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: Implicaitons for the pathogenesis and treatment of Alzheimer's disease. PNAS 98(18): 10273-10278.
	х	DeMattos et al. (2001) "Peripheral Anti Abeta Antibody Alters CNS and Plasma Abeta Clearance and Decreases Brain Abeta Bruden in a Mouse Model of Alzheimer's Disease" PNAS 10: 1-6.

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

## Notice of References Cit d

Application/Control No. 09/674,913	Applicant(s)/Patent Under Reexamination GAUDERNACK ET AL.		
Examiner	Art Unit		
Christopher Nichols, Ph.D.	1647	Page 2 of 5	

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	O	US-			
	۵	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q				,	
	R					
	S					
	Т					

#### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)							
	U	Esiri (2001) Is an Effective Immune Intervention for Alzheimer's Disease in Prospect? Trends in Pharm Science 22(1): 2-3.							
	٧	Younkin (2001) Amyloid beta Vaccination: Reduced Plaques and Improved Cognition. Nature Medicine 7(1):18-19.							
	V	Games et al. (1995) Alzheimer-type Neuropathology in Transgenic Mice overexpressing V717F beta-amyloid precursor protein. Nature 373(6514): 523-527.							
	х	Schenk et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP Mouse. Nature 400:173-177.							

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

# Notice of R ferences Cited

Application/Control No.

09/674,913

Applicant(s)/Patent Under Reexamination GAUDERNACK ET AL.

Examiner

Christopher Nichols, Ph.D.

Applicant(s)/Patent Under Reexamination GAUDERNACK ET AL.

Page 3 of 5

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	٦	US-			
	K	US-			
	L	US-			
	М	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Ρ					
	σ					
	R					
	S					
	Т					

#### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
,	υ	Small et al. (2001) Alzheimer's Disease and Abeta Toxicity: from top to bottom. Nat Rev Neurosci. 2(8): 595-8.
	٧	Chapman (2000) Model Behavior. Nature 408: 915-916.
	W	Grubeck-Lobenstein et al. (2000) Immunization of beta-amyloid: could T-cell activation have a harmful effect? TINS 23: 114.
	х	Friedland et al. (1997) Neuroimaging of Vessel Amyloid in Alzheimer's Disease in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Science, NY, NY.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

### Notic of References Cited

Application/Control No.

O9/674,913

Examiner

Christopher Nichols, Ph.D.

Applicant(s)/Patent Under Reexamination GAUDERNACK ET AL.

Art Unit
Page 4 of 5

#### U.S. PATENT DOCUMENTS

	C.C. FALLY DOCUMENTO						
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification		
	Α	US-					
	В	US-					
	ပ	US-					
	D	US-					
	Ε	US-					
	F	US-					
	G	US-					
	Н	US-					
	1	US-					
	J	US-					
	К	US-					
	L	US-					
	М	US-					

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N			•		
	0					
	Р					
	Q					
	R					
	S					
	T					

#### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)				
	υ	Frenkel et al. (1998) N-terminal EFRH Sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. Journal of Neuroimmunology 88: 85-90.				
1	\	Frenkel et al. (2000) Immunization against Alzheimer's beta-amyloid plaques via EFRH phage adminstration. PNAS 97(21) 11455-11459.				
	w	Frenkel et al. (1999) High Affinity Binding of Monoclonal Antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. Journal of Neuroimmunology 95: 136-142.				
	х	ELAN "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792." Press Release (28.Jan.2002) and ELAN "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration" Press Release (1.Mar.2002)				

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

## Notice of References Cited

Application/Control No.

O9/674,913

Examiner

Christopher Nichols, Ph.D.

Applicant(s)/Patent Under Reexamination
GAUDERNACK ET AL.

Art Unit
Page 5 of 5

#### **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	Н	US-			
	í	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	S					
	Т					

#### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)			
	U	Tanaka et al. (1998) NC-1900, an active Fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats. European Journal of Pharmocology 352: 135-142.			
	٧	Tennet et al. (1995) Serum amyloid P component precents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. PNAS 92: 4299-4303.			
	w	Chen et al. (1998) Neurodegenerative Alzheimer-like pathology in PDAPP 717VF transgenic mice. Progress in Brain Research 117: 327-334.			
	х				

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.